<code id='397E9A47AC'></code><style id='397E9A47AC'></style>
    • <acronym id='397E9A47AC'></acronym>
      <center id='397E9A47AC'><center id='397E9A47AC'><tfoot id='397E9A47AC'></tfoot></center><abbr id='397E9A47AC'><dir id='397E9A47AC'><tfoot id='397E9A47AC'></tfoot><noframes id='397E9A47AC'>

    • <optgroup id='397E9A47AC'><strike id='397E9A47AC'><sup id='397E9A47AC'></sup></strike><code id='397E9A47AC'></code></optgroup>
        1. <b id='397E9A47AC'><label id='397E9A47AC'><select id='397E9A47AC'><dt id='397E9A47AC'><span id='397E9A47AC'></span></dt></select></label></b><u id='397E9A47AC'></u>
          <i id='397E9A47AC'><strike id='397E9A47AC'><tt id='397E9A47AC'><pre id='397E9A47AC'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:11348
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

          CarstenSnejbjerg/BloombergLONDON—TheinvestmentarmofNovoNordisk’sparentfoundationisbuyingdrugmanufact

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Why Novartis is going to walk from its acquisition of MorphoSys

          MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc